ASX:CSLBiotechs
Pediatric ANDEMBRY Phase 3b Success Might Change The Case For Investing In CSL (ASX:CSL)
CSL has reported positive top-line Phase 3b results for ANDEMBRY (garadacimab-gxii) in children aged 2 to 11 years with hereditary angioedema, showing a safety profile consistent with earlier studies and treatment responses that kept most participants attack-free over 12 months.
This progress in extending ANDEMBRY’s use to younger pediatric patients highlights CSL’s push to deepen its presence in rare disease prophylaxis through factor XIIa inhibition.
We’ll now examine how the positive...

